Antithrombotic therapy in acute coronary syndromes: Guidelines translated for the clinician

Journal of Thrombosis and Thrombolysis

Volumn 29, Issue 4, 2010, Pages 516-528

  Gharacholou, S Michael ^a   Lopes, Renato D ^a   Washam, Jeffrey B ^a   Newby, L Kristin ^a   James, Stefan K ^b   Alexander, John H ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute coronary syndromes; Antithrombotic therapy; Guidelines

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CANGRELOR; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; RIVAROXABAN; STREPTOKINASE; TICAGRELOR; TIROFIBAN; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY INTERVENTION; HEART MUSCLE ISCHEMIA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THERAPY DELAY; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; CHEMICALLY INDUCED DISORDER; EUROPE; RISK FACTOR; UNITED STATES;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; EUROPE; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; UNITED STATES;

EID: 77955488707     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-009-0437-9     Document Type: Review

References (60)

1. World Health Organization (2003) Prevention of recurrent heart attacks and strokes in low and middle income populations: evidence-based recommendations for policy makers and health professionals. WHO Press, Geneva
2. Libby P (2001) Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365-372
3. Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 50: e1-e157
4. Antman EM, Anbe DT, Armstrong PW et al (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 110:588-636
5. Cannon CP, Weintraub WS, Demopoulos LA et al (2001) Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 344:1879-1887
6. Skolnick AH, Alexander KP, Chen AY et al (2007) Characteristics, management, and outcomes of 5, 557 patients age > or = 90 years with acute coronary syndromes: results from the CRUSADE Initiative. J Am Coll Cardiol 49:1790-1797
7. Mehta SR, Cannon CP, Fox KA et al (2005) Routine versus selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 293:2908-2917
8. Alexander KP, Newby LK, Cannon CP et al (2007) Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 115:2549-2569
9. Pfisterer M, Brunner-LaRocca HP, Buser PT et al (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drugeluting versus bare-metal stents. J Am Coll Cardiol 48:2584-2591
10. Douglas PS, Brennan JM, Anstrom KJ et al (2009) Clinical effectiveness of coronary stents in elderly persons: results from 262, 700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 53:1629-1641
11. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
12. James S, Stenestrand U, Lindbäck J et al (2009) Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 360:1933-1945
13. Alexander KP, Chen AY, Roe MT et al (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108-3116
14. Subherwal S, Bach RG, Chen AY et al (2009) Baseline risk of major bleeding in non-ST-segment elevation myocardial infarction: the CRUSADE (can rapid risk stratification of unstable angina patients suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score. Circulation 119:1873-1882
15. Chase AJ, Fretz EB, Warburton WP et al (2008) Association of the arterial access site at angioplasty with transfusion and mortality: the M. O. R. T. A. L (mortality benefit of reduced transfusion after percutaneous coronary intervention via the arm or leg) study. Heart 94:1019-1025
16. Roy P, Bonello L, Torguson R et al (2008) Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 102:1614-1617
17. Chan MY, Sun JL, Newby LK et al (2009) Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST elevation myocardial infarction. Circulation 119:3110-3117
18. Becker RC (2002) Antithrombotic therapy after myocardial infarction. N Engl J Med 347:1019-1022
19. Bassand JP, Hamm CW, Ardissino D et al (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660
20. Van de Werf F, Bax J, Betriu A et al (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29:2909-2945
21. Harrington RA, Becker RC, Cannon CP et al (2008) Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 133:670S-707S
22. Goodman SG, Menon V, Cannon CP et al (2008) Acute ST-segment elevation myocardial infarction: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 133:708S-775S
23. Popovic JR, Kozak LJ (2000) National hospital discharge survey: annual summary, 1998. Vital Health Stat 13:1-194
24. Antman EM, Cohen M, Bernink PJ et al (2000) The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284:835-842
25. Eagle KA, Lim MJ, Dabbous OH et al (2004) A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291:2727-2733
26. Boersma E, Pieper KS, Steyerberg EW et al (2000) Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT investigators. Circulation 101:2557-2567
27. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502
28. Carruthers KF, Dabbous OH, Flather MD et al (2005) Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart 91:290-298
29. Roe MT, Parsons LS, Pollack CV Jr et al (2005) Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 165:1630-1636
30. Mehta RH, Roe MT, Chen AY et al (2006) Recent trends in the care of patients with non-T-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 166:2027-2034
31. Yusuf S, Mehta SR, Chrolavicius S et al (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476
32. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774-782
33. Petersen JL, Mahaffey KW, Hasselblad V et al (2004) Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 292:89-96 (Pubitemid 38923799)
34. Mehta SR, Steg PG, Granger CB et al (2005) Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra study in percutaneous coronary intervention: a randomized evaluation (ASPIRE) pilot trial. Circulation 111:1390-1397
35. Ferguson JJ, Califf RM, Antman EM et al (2004) Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292:45-54
36. White HD, Kleiman NS, Mahaffey KW et al (2006) Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the superior yield of the new strategy of enoxaparin, revascularization and glycoprotein IIb/IIIa inhibitors (SYNERGY) trial. Am Heart J 152:1042-1050
37. DeWood MA, Spores J, Notske R et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303:897-902
38. Antman EM, Hand M, Armstrong PW et al (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51:210-247
39. Van de Werf F, Ardissino D, Betriu A et al (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of cardiology. Eur Heart J 24:28-66
40. de Bono DP, Simoons ML, Tijssen J et al (1992) Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 67:122-128
41. Eisenberg PR (1992) Role of heparin in coronary thrombolysis. Chest 101:131S-139S
42. Collins R, Peto R, Baigent C, Sleight P (1997) Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336:847-860
43. Mahaffey KW, Granger CB, Collins R et al (1996) Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 77:551-556
44. Yusuf S, Mehta SR, Xie C et al (2005) Effects of reviparin, a lowmolecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293:427-435
45. Antman EM, Morrow DA, McCabe CH et al (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354:1477-1488
46. Murphy SA, Gibson CM, Morrow DA et al (2007) Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28:2077-2086
47. Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519-1530
48. Stone GW, Witzenbichler B, Guagliumi G et al (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218-2230
49. Chen ZM, Jiang LX, Chen YP et al (2005) Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607-1621
50. Sabatine MS, Cannon CP, Gibson CM et al (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179-1189
51. Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 323:147-152
52. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002) Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347:969-974
53. Alexander JH, Becker RC, Bhatt DL et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 119:2877-2885
54. Mega JL, Braunwald E, Mohanavelus S et al (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS-ACS TIMI 46): a randomised, double-blind, phase II trial. Lancet 374:29-38
55. Murphy SA, Antman EM, Wiviott SD et al (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 29:2473-2479
56. Greenbaum AB, Grines CL, Bittl JA et al (2006) Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am Heart J 151:689. e1-689. e10
57. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057
58. Giugliano RP, White JA, Bode C et al (2009) Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360:1-15
59. Mehta SR, Bassand JP, Chrolavicius S et al (2008) Design and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156:1080-1088
60. Double doses of clopidogrel better than standard dose for heart patients undergoing angioplasty, an international study find [press release]. Barcelona, Spain: ESC Congress 2009; August 30, 2009. http://www.escardio.org/about/press/ press-releases/esc09-barcelona/Pages/esc-2009-Mehta-Current%20Oasis%207.aspx. Accessed 21 Oct. 2009